NeuroVision shares common strategic, research, clinical and commercial goals with the broader academic and industry players focused on neurodegeneration, and has engaged in research and collaboration agreements and projects with many institutions and companies.
- Research Agreements with 24 Academic Institutions
- 4 Novel Blood Biomarker License Agreements
- Critical Antibody Supply and Research Agreement
- Collaboration Agreements with 5 Pharmaceutical Companies